Celiprolol is a selective beta-1 adrenergic receptor blocker with additional beta-2 agonist activity, primarily used in the treatment of hypertension and angina pectoris. It helps reduce heart rate and blood pressure while causing mild vasodilation due to its beta-2 activity. Celiprolol was first synthesized in the 1980s and later approved for clinical use to provide cardioprotective effects with fewer side effects compared to traditional beta-blockers. It is effective in reducing cardiovascular risk in patients with hypertension and preventing angina attacks. The drug is administered orally, typically once daily, and has a favorable safety profile. Its selective action makes it suitable for patients with respiratory conditions, as it minimally affects beta-2 receptors in the lungs. Celiprolol also demonstrates antioxidant and vascular protective properties, contributing to improved endothelial function. Clinical studies have shown its efficacy in long-term blood pressure control and reduction of cardiovascular events. Its introduction marked an important advancement in modern antihypertensive therapy. Today, Celiprolol remains a valuable option for managing cardiovascular disorders, combining efficacy with safety.
